The Protective Barrier to Resistance of Darunavir in a Convenient STR1

Dosing & Administration

 

The smallest darunavir coformulation available.

One tablet, once daily with food.

Drugs that are contraindicated

Alpha 1-adrenoreceptor agonist alfuzosin
Antianginal ranolazine
Antiarrhythmic dronedarone
Anticonvulsants carbamazepine, phenobarbital, phenytoin
Anti-gout colchicine in patients with renal or hepatic impairment
Antimycobacterial rifampin
Antipsychotics lurasidone, pimozide
Ergot derivatives dihydroergotamine, ergotamine, methylergonovine
GI motility agent cisapride
Hepatitis C direct-acting antiviral elbasvir/grazoprevir
Herbal product St. John’s wort
Lipid modifying agents lomitapide, lovastatin, simvastatin
PDE-5 inhibitor sildenafil for treatment of pulmonary arterial hypertension
Sedative/hypnotics midazolam (oral), triazolam

Coadministration not recommended*

Anticoagulant rivaroxaban
Anticonvulsants eslicarbazepine, oxcarbazepine
Antifungal voriconazole
Antimycobacterials rifapentine, rifabutin
Systemic/inhaled/nasal/ophthalmic corticosteroids betamethasone, budesonide, ciclesonide, dexamethasone, fluticasone, methylprednisolone, mometasone, triamcinolone
Hepatitis C direct-acting antivirals glecaprevir/pibrentasvir, simeprevir
Immunosuppressant/neoplastic everolimus
Inhaled beta agonist salmeterol
PDE-5 inhibitor avanafil
Platelet aggregation inhibitor ticagrelor

*Recommendations are based on drug interaction trials conducted with components of SYMTUZA®, as individual agents or in combination, or are predicted interactions.

GI=gastrointestinal; PDE-5=phosphodiesterase type 5; STR=single-tablet regimen.

Reference: 1. SYMTUZA® [package insert]. Titusville, NJ: Janssen Therapeutics, Division of Janssen Products, LP; 2019.